099190 - i-SENS, Inc.

099190 Summary

Medical Devices

Stock Price & Overview

₩16,470 +0 (+0.00%) Close · Sep 4, 2026 KST

KOSDAQ | ₩KRW | Close: ₩16,470 ≈ US$12 · Market cap ₩0.5tn (≈ $338m)

099190 Financial Statements

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Total Revenue	315.4	291.1	265.1	264.8	232.9	203.7	189.8	173.0	157.0	132.5	101.9
Cost of Revenue	190.2	177.6	159.1	159.4	130.9	107.9	103.1	95.3	87.8	70.6	56.5
Gross Profit	125.3	113.5	106.1	105.5	102.1	95.8	86.8	77.7	69.2	61.8	45.4
Selling, General & Administrative	—	—	—	85.7	67.2	65.3	56.6	50.3	46.4	36.1	26.0
Operating Income	7.9	2.7	10.9	19.8	34.8	30.5	30.2	27.4	22.8	25.7	19.4
Finance Income	4.2	7.4	5.8	4.7	4.4	1.9	1.1	2.3	1.6	1.5	0.8
Finance Costs	8.9	8.2	7.2	7.7	2.2	4.9	2.2	2.8	2.4	2.1	1.5
Pretax Income	-10.7	1.7	6.1	19.2	30.7	34.9	29.6	26.4	19.5	22.7	18.9
Income Tax Expense	-4.0	3.6	2.7	3.2	5.6	7.6	6.3	4.0	4.3	5.1	4.5
Net Income	-6.7	-2.0	3.4	15.9	25.2	27.3	23.3	22.4	15.1	17.5	14.5
Total Comprehensive Income	-7.1	34.0	2.0	18.8	52.2	23.8	24.0	22.4	13.5	17.1	13.5

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Total Assets	577.7	590.9	498.8	449.6	429.2	307.0	270.0	252.0	234.1	217.6	179.8
Current Assets	253.7	270.9	207.5	217.2	207.7	159.9	129.0	110.8	95.8	94.9	77.5
Cash & Cash Equivalents	45.0	67.6	45.3	61.6	47.2	30.5	34.5	27.0	27.5	25.5	23.2
Inventories	74.5	76.0	83.5	80.7	50.6	34.5	31.7	30.5	29.1	31.6	21.1
Trade Receivables	67.3	65.5	58.3	52.0	49.6	39.3	45.2	48.8	36.6	—	—
Non-current Assets	319.3	315.3	281.0	232.4	221.5	147.1	141.1	141.3	138.3	122.7	102.3
Property, Plant & Equipment	256.1	244.8	200.0	177.6	171.1	104.2	102.0	102.1	98.7	80.6	72.3
Intangible Assets	32.8	32.5	38.5	15.0	14.1	14.1	16.0	20.1	19.3	23.8	1.7
Total Liabilities	239.3	247.9	195.3	144.8	144.4	83.9	69.0	68.8	68.9	63.2	47.6
Current Liabilities	166.9	112.1	139.3	74.6	38.4	31.6	41.8	28.2	25.8	32.2	18.2
Non-current Liabilities	72.4	135.8	56.0	70.3	106.0	52.3	27.2	40.6	43.1	31.0	29.4
Total Equity	338.3	343.0	303.5	304.8	284.7	223.1	201.1	183.3	165.2	154.4	132.2
Share Capital	13.9	13.8	13.8	6.9	6.9	6.9	6.9	6.9	6.9	6.9	6.9
Retained Earnings	198.8	208.2	211.6	213.9	198.5	176.8	154.3	133.1	111.5	97.2	79.2

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Cash from Operating Activities	20.1	23.0	13.0	6.7	17.2	34.6	38.0	19.5	22.4	11.7	22.6
Cash from Investing Activities	-35.7	-40.3	-63.8	16.5	-59.6	-46.2	-19.4	-12.6	-27.9	-14.2	-24.5
Purchase of Property, Plant & Equipment	27.7	15.2	42.1	22.0	47.6	7.6	6.9	8.8	23.7	7.6	13.6
Cash from Financing Activities	-6.5	38.8	34.9	-9.2	58.3	9.6	-11.0	-8.2	8.2	4.2	-0.1
Dividends Paid	2.8	2.8	4.8	4.1	3.4	2.7	2.0	1.4	1.4	—	—
Net Change in Cash	-22.1	21.4	-15.8	13.9	15.9	-1.9	7.5	-1.2	2.6	1.7	-2.0

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Total Revenue	88.7	75.1	83.7	78.7	76.8	76.3	81.3	71.5	69.9	68.4
Cost of Revenue	50.3	43.3	49.6	49.8	45.3	45.5	53.4	41.7	41.4	41.2
Gross Profit	38.4	31.8	34.1	28.9	31.5	30.8	27.9	29.9	28.5	27.2
Selling, General & Administrative	31.8	30.9	—	28.0	29.8	27.5	31.9	26.0	26.6	26.4
Operating Income	6.6	0.9	2.1	0.9	1.7	3.2	-3.9	3.8	2.0	0.8
Finance Income	0.6	2.0	1.2	1.0	0.5	1.5	4.3	0.6	1.3	1.1
Finance Costs	3.5	2.1	1.9	1.6	2.9	2.6	1.0	0.9	2.8	3.5
Pretax Income	4.7	1.9	-13.9	1.3	-1.1	2.9	0.3	1.6	-0.2	-0.1
Income Tax Expense	0.8	0.3	-5.0	2.1	1.8	0.7	4.6	-0.9	0.2	0.1
Net Income	4.0	1.6	-8.9	-0.8	0.8	2.2	-2.3	0.7	0.0	-0.4
Total Comprehensive Income	5.7	5.1	-6.7	0.9	-3.8	2.5	30.7	-1.9	2.7	2.5

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Total Assets	599.1	591.0	577.7	583.5	569.0	583.0	590.9	550.2	555.2	498.7
Current Assets	257.0	259.6	253.7	249.4	246.7	258.3	270.9	257.1	256.8	208.5
Cash & Cash Equivalents	58.6	48.2	45.0	56.1	59.8	54.3	67.6	69.8	85.2	53.8
Inventories	86.5	80.5	74.5	76.5	76.3	74.2	76.0	83.5	81.2	81.1
Trade Receivables	71.0	67.9	67.3	67.1	62.4	63.3	65.5	52.9	55.6	53.1
Non-current Assets	337.5	326.8	319.3	329.4	317.6	320.0	315.3	276.6	288.2	280.0
Property, Plant & Equipment	273.0	263.8	256.1	251.8	249.2	247.2	244.8	202.6	202.1	199.1
Intangible Assets	33.4	34.0	32.8	37.1	30.8	32.5	32.5	38.2	40.9	40.0
Total Liabilities	235.2	234.6	239.3	238.1	231.2	242.3	247.9	237.9	239.7	195.4
Current Liabilities	145.9	152.5	166.9	149.3	142.8	105.1	112.1	138.1	140.3	138.6
Non-current Liabilities	89.2	82.1	72.4	88.8	88.4	137.2	135.8	99.8	99.3	56.7
Total Equity	364.0	356.5	338.3	345.3	337.8	340.7	343.0	312.2	315.6	303.4
Share Capital	14.4	14.4	13.9	13.9	13.9	13.8	13.8	13.8	13.8	13.8
Retained Earnings	201.8	197.9	198.8	206.5	206.8	208.0	208.2	209.4	208.5	208.5

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Cash from Operating Activities	8.0	-1.6	13.3	6.2	-2.0	2.6	2.2	7.3	3.8	9.7
Cash from Investing Activities	8.4	-5.7	-23.6	-11.7	13.1	-13.5	-4.7	-19.2	-16.3	-0.2
Purchase of Property, Plant & Equipment	11.7	7.6	8.2	5.7	7.8	6.0	4.0	5.9	3.3	2.1
Cash from Financing Activities	-7.0	9.4	-1.2	0.2	-2.6	-2.9	-1.6	-0.6	42.4	-1.5
Dividends Paid	—	—	0.0	0.0	—	—	0.0	0.0	2.8	0.0
Net Change in Cash	9.4	2.1	-11.5	-5.3	8.6	-13.8	-4.0	-12.5	29.9	8.0

Consolidated (CFS), from DART. 11 fiscal years and 10 quarters. Accounts matched on IFRS account_id, not Korean labels, so the same line holds across years where the Korean wording changed. Quarterly figures are three-month values: income quarters from DART's three-month column, cash-flow quarters differenced from DART's cumulative figures, and Q4 as annual minus nine-month cumulative.

099190 Growth

FY2025 ₩bn	Latest	1-yr	3-yr CAGR	5-yr CAGR	10-yr CAGR
Revenue	315.4	+8.3%	+6.0%	+9.1%	+12.0%
Operating income	7.9	+196.7%	-26.4%	-23.7%	-8.6%
Net income	-6.7	—	—	—	—
EPS	₩-233	—	—	—	—
Operating cash flow	20.1	-12.4%	+44.6%	-10.3%	-1.1%
Shareholders' equity	338.3	-1.4%	+3.5%	+8.7%	+9.9%

Compound annual growth from the DART annual statements on this page. n/m where either end of the period is a loss or missing. EPS uses today's share count for every year.

099190 Profitability

Ratio	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Gross margin	39.7%	39.0%	40.0%	39.8%	43.8%	47.0%
Operating margin	2.5%	0.9%	4.1%	7.5%	15.0%	15.0%
Net margin	-2.1%	-0.7%	1.3%	6.0%	10.8%	13.4%
Return on equity	-2.0%	-0.6%	1.1%	5.4%	9.9%	12.9%
Return on assets	-1.1%	-0.4%	0.7%	3.6%	6.8%	9.5%
Operating cash flow / revenue	6.4%	7.9%	4.9%	2.5%	7.4%	17.0%
Capex / revenue	8.8%	5.2%	15.9%	8.3%	20.4%	3.7%

Margins divide by revenue for the same year. Return on equity and assets divide net income by the average of that year's and the prior year's balance, as DART reports them (consolidated, including minority interests).

Similar to 099190

Symbol	Last Price
096530Seegene, Inc.	₩31,900 +1.1%
491000Livs Med, Inc.	₩34,500 +3.6%
041830In Body Co., Ltd.	₩61,100 +2.5%
445680Curiox Biosystems Co., Ltd.	₩47,650 -1.5%
458870Seers Co., Ltd.	₩21,350 +3.1%
137310SD Biosensor	₩6,160 -0.3%
377740Bio Note, Inc.	₩4,790 -0.2%
340570T & L Co., Ltd.	₩29,650 +1.2%
336570WON Tech Co., Ltd.	₩4,905 +0.9%
174900Ab Clon, Inc.	₩21,600 +5.9%

Compare all 13 in Medical Devices

What a US investor should know

Trading hours09:00–15:30 KST — 20:00–02:30 US Eastern the night before.
Daily limitKorean stocks can move at most ±30% in a session before trading halts.
Getting exposureKRX shares are not directly tradable in most US brokerage accounts. The usual routes are Korea ETFs or an international account.
ReportingKorean issuers file to DART, not the SEC. Half-year and quarterly reports land about 45 days after period end.